| View Larger Image | Targeted Interference with Signal Transduction Events (Recent Results in Cancer Research) | Hardcoverby B. Groner (Editor)
| List Price: | $129.00 | | Price: | $65.19 | | You Save: | $63.81 (49%) | | | Available: | Usually ships in 24 hours |
| | Binding: | Hardcover | | Publisher: | Springer | | Edition: | 1st Edition | | Page Count: | 188 Pages | | Publication Date: | July 11, 2007 | | Sales Rank: | 3,507,240rd |
|
ACCESSORIES |
| Cytokines in the Genesis and Treatment of Cancer (Cancer Drug Discovery and Development)
by Michael A. Caligiuri (Editor), Michael T. Lotze (Editor)
Cytokines in the Genesis and Treatment of Cancer provides a comprehensive picture of the dual role of host responses in promoting and inhibiting tumor progression. This volume represents an important investigation into the emerging intersection of cancer biology and cancer immunology. Divided into four sections, the volume’s first three parts focus on cytokines in the genesis of cancer. The final section describes the notable progress — both in animal models and humans — in demonstrating...
| 
| Acute Promyelocytic Leukemia: Molecular Genetics, Mouse Models and Targeted Therapy (Current Topics in Microbiology and Immunology)
by Pier Paolo Pandolfi (Editor), Peter K. Vogt (Editor)
Over the past 10 years, work on acute promyelocytic leukemia (APL) has become the paradigm of translational research that began with the discovery of a recurrent chromosomal translocation, followed by the identification of the genes and proteins involved, finding their molecular functions in transcriptional control, establishing mouse models and culminating in the development of targeted therapy.
| 
| Regional Cancer Therapy (Cancer Drug Discovery and Development)
by Peter M. Schlag (Editor), Ulrike Stein (Editor), M.M. Eggermont (Editor)
This volume provides a biological and pharmacological background for regional cancer therapy, strategies and techniques for regional therapies, and specific indications and results for different tumor entities. Clinical trial concepts and detailed treatment protocols are also presented. Part I describes biological and pharmacological fundamentals for therapy and introduces laboratory models for isolated limb and organ perfusion. Topics introduced in Part II include interventional...
|
|
EDITORIAL REVIEWS |
Product Description
Two aspects of biological research are major contributors to the progress in the understanding of cancer etiology and the development of new and improved cancer drugs. The sequencing of the human genome provides us with a basic overview of all our genes and gene products, and the insights into signaling pathways allow us to align crucial components of cellular regulation into an ordered functional context. A comparison of the genes in normal and in tumor cells shows that mutations in the DNA of a limited set of genes are responsible for the multiple stages of tumorigenesis and metastasis. Many of the affected genes, including oncogenes, tumor suppressor genes and genome stability genes, can be fitted into pathways. They encode molecules that stimulate tumor cell division or inhibit their death. Matching of therapeutic intervention with insights into the underlying molecular disease mechanism has already led to the development of drugs such as Herceptin and Glivec. The deregulation of pathways as a consequence of the altered biochemical function of mutated cancer genes provides the conceptual basis for future progress. Will it be possible to extrapolate this principle and derive more efficient drugs targeting cancer pathway components? Promising cell surface molecules, potential targets of monoclonal antibodies, and intracellular molecules with enzymatic activity, potential targets for low-molecular-weight synthetic inhibitors, have been identified. Our ability to predict the consequences of inhibition of such components, however, is still limited. For this reason, the development of targeted drugs remains a complex process, comprising rational and empirical elements. The state of development of tomorrow's cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities, is described in this book. |
|
